HK Stock Market Move | Insilico (03696) rose more than 7% in early trading and partnered with CMS in the field of central nervous system for AI-driven drug discovery.

INSILICO (03696) rose over 7% in early trading, as of the time of writing, it has increased by 6.45%, reaching 45.58 Hong Kong dollars, with a trading volume of 1.78 billion Hong Kong dollars. On the news front, on July 13th, according to an announcement on INSILICO's official Weibo account, the company announced a new AI-driven drug discovery collaboration with CMS (00867) in the field of central nervous system. This collaboration targets a large market indication and is based on the innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, both parties will combine INSILICO's validated AI platform and AI-enabled innovative drug development capabilities, as well as CMS's experienced R&D team and deep understanding of the disease field, to jointly advance the development of this research project. At the same time, INSILICO is expected to receive a total of approximately 1.2 billion RMB in milestone payments and net sales sharing. This collaboration signifies a further deepening of the relationship between the two parties, aiming to leverage the complementary strengths of both sides in the full value chain of drug discovery, clinical development, and commercialization.